Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) A substudy of the phase 2 obesity trial specifically examined GLP3s effects on liver fat in participants with metabolic dysfunction-associated steatotic liver disease[12]: Mean relative liver fat reduction of 82.4% with 12 mg dose at 24 weeks 86% of participants on 12 mg achieved normal liver fat levels (below 5%) at 24 weeks Liver fat reductions significantly correlated with improvements in insulin sensitivity, abdominal fat, and metabolic parameters Dose-dependent improvements observed across all dose groups compared to placebo These results suggest potential therapeutic applications beyond weight management, addressing hepatic complications of obesity and metabolic syndrome
Algorithms that consider baseline BMI category, visceral-fat distribution, renal function, gut-hormone profiles and behavioral traits could help predict responders versus non-responders
Manage Metabolic Stress Cutting is stressful on the body
That model skips the very steps that make these drugs safe: a hands-on exam, baseline labs, an EKG when appropriate, and a real review of your metabolism, thyroid history, and cardiovascular health, which matters especially with a stimulant like phentermine and with the thyroid contraindications tied to GLP-1 therapy
Haas sit down with Jay Campbell to break down the truth about GLP peptides, whats really happening behind the scenes, and where the future of fat loss and performance is heading
Conclusion: A Side Effect Worth Noting - But Often Temporary While not officially listed among Mounjaros side effects, feeling cold has become one of the most commonly discussed experiences in patient forums